Second Genome
2009
FOUNDED
PRIVATE
STATUS
51-60
EMPLOYEES
Grant
LATEST DEAL TYPE
14
INVESTORS
Description
Provider of microbial profiling services designed to to improve health & wellness. The company's microbiome data platform utilizes microbiome biology, bioninformatics, computation and machine learning to identify prospective therapeutic lead candidates, bacteria, peptides and metabolites which benefit human health, enabling therapeutic candidates to be advanced through pharmaceutical clinical programs. The company's platform is also utilized in agriculture as a resource for mining the agricultural microbiome.
Website
Formerly Known As
Phylotech
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 341 Allerton Avenue
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Second Genome’s full profile, request a free trial.
Second Genome Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Grant | 03-Oct-2017 | 000.00 | Completed | Clinical Trials - Phase 1 | ||
| 4. Later Stage VC (Series B) | 13-Jul-2016 | 000.00 | 000.00 | 0000 | Completed | Clinical Trials - Phase 1 |
| 3. Early Stage VC (Series A) | 07-Jun-2013 | 000.00 | 000.00 | 000.00 | Completed | Startup |
| 2. Early Stage VC (Series A) | 09-Aug-2011 | $5M | $6.24M | 000.00 | Completed | Startup |
| 1. Seed Round | 07-Jul-2010 | $1.24M | $1.24M | 00.00 | Completed | Startup |
Second Genome Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 000,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Seed | 5,607,290 | $0.000100 | $0.02 | $0.22 | $0.22 | 1x | $0.22 | 2.12% |
Second Genome Competitors (25)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Whole Biome | Venture Capital-Backed | San Francisco, CA | 00 | 000.00 | 00000000000 | 000.00 |
| 00000000 | Corporate Backed or Acquired | Cambridge, MA | 0 | 00000000000 | ||
| 00000 000000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000000 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 000.00 | 00000000000 | 000.00 |
| 00000 | Venture Capital-Backed | Ness Ziona, Israel | 00 | 0000 | 00000000000 | 0000 |
Second Genome Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Digitalis Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Lifeforce Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Lifeforce Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Lightstone Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Matthew Winkler | Angel (individual) | Minority | 000 0000 | 000000 0 |
Second Genome Executive Team (13)
6 Former Executives
You’re viewing 5 of 13 executives. Get the full list »Second Genome Board Members (11)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Bradley Margus | Self | Board Member | 000 0000 | |
| Carole Nuechterlein JD | Roche Venture Fund | Board Member | 000 0000 | |
| Corey Goodman Ph.D | Self | Chairman & Co-Founder | 000 0000 | |
| Elaine Jones Ph.D | Pfizer Ventures | Board Member | 000 0000 | |
| Geoffrey Smith JD | Digitalis Ventures | Board Observer | 000 0000 |
3 Former Board Members
You’re viewing 5 of 11 board members. Get the full list »